Halozyme Therapeutics (HALO) Liabilities and Shareholders Equity (2010 - 2026)

Halozyme Therapeutics (HALO) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $2.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 21.68% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $9.5 billion (up 13.49% YoY), while the FY2025 annual figure was $2.5 billion, up 22.38% from the prior year.
• Liabilities and Shareholders Equity grew to $2.7 billion in Q1 2026 per HALO's latest filing, from $2.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.7 billion in Q1 2026 and bottomed at $1.2 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 73.65% — and 2023, when it retreated 5.88%.
• Halozyme Therapeutics' Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then fell by 5.88% to $1.7 billion in 2023, then gained by 19.05% to $2.1 billion in 2024, then rose by 22.38% to $2.5 billion in 2025, then increased by 5.84% to $2.7 billion in 2026.
• Business Quant data shows HALO's Liabilities and Shareholders Equity at $2.7 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.2 billion in Q3 2025.